Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR...

Area of Science:

• Oncology
• Pharmacology
• Computational Biology

Background:

• Developing targeted drug combinations is crucial for cancer treatment.
• Mathematical models and computerization can aid in simulating biological phenomena and optimizing experimental conditions.

Purpose of the Study:

• To propose and illustrate the concept of 'multiparameter trials' for drug development.
• To determine optimized doses and schedules for everolimus and sorafenib in solid tumors using a model-based approach.
• To maximize the predicted benefit/toxicity ratio for anticancer agent combinations.

Main Methods:

• Collection of biological, radiological, and clinical data for modeling purposes.
• Utilizing the academic EVESOR trial as an illustration.
• Employing mathematical models to simulate drug effects and optimize dosing strategies.

Main Results:

• The study outlines a framework for model-based drug development.
• It demonstrates the potential for optimizing drug combinations like everolimus and sorafenib.
• The approach aims to enhance the benefit/toxicity ratio in cancer patients.

Conclusions:

• Multiparameter trials represent a novel approach to model-based drug development.
• Mathematical modeling can guide the optimization of targeted anticancer drug combinations.
• This methodology offers a proof of concept for future combination therapy development.